Trial Profile
ZEST II for Osteoporotic Fracture Prevention
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Fracture; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms ZEST II
- 07 Sep 2022 Status changed from active, no longer recruiting to completed.
- 08 Jan 2021 Planned End Date changed from 1 Jul 2021 to 1 Mar 2023.
- 08 Jan 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Sep 2022.